Finding new treatments for Jansen’s metaphyseal chondrodysplasia
Identification of selective inhibitors of PTH-receptor for Jansen’s metaphyseal chondrodysplasia
This study is looking at new tiny medicines that could help fix the problems caused by a gene mutation in people with Jansen’s metaphyseal chondrodysplasia (JMC), focusing on how these medicines might help the growth of the jaw joint and improve overall health.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10694007 on NIH RePORTER |
What this research studies
This research aims to develop and test small molecules that can inhibit the abnormal activation of the parathyroid hormone type 1 receptor (PTHR) associated with Jansen’s metaphyseal chondrodysplasia (JMC). By using advanced techniques, the researchers will analyze how these molecules can restore normal signaling in cells affected by specific receptor mutations. The study will also investigate how these treatments can influence the growth and development of the temporomandibular joint (TMJ) in engineered tissues. This interdisciplinary approach combines pharmacology, bioengineering, and oral sciences to better understand and potentially correct the underlying cellular defects in JMC.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Jansen’s metaphyseal chondrodysplasia, particularly those with specific mutations in the PTHR gene.
Not a fit: Patients without Jansen’s metaphyseal chondrodysplasia or those with different underlying conditions affecting bone growth may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options for patients with Jansen’s metaphyseal chondrodysplasia, improving their bone and joint health.
How similar studies have performed: While the approach of using small molecules to target receptor signaling is established, the specific application to Jansen’s metaphyseal chondrodysplasia represents a novel and untested area.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Vilardaga, Jean-Pierre — University of Pittsburgh at Pittsburgh
- Study coordinator: Vilardaga, Jean-Pierre
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.